LyndonZhang
2018-12-20
$DBV Technologies S.A.(DBVT)$ 这就是大跌的原因
免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
LyndonZhang
2018-12-20
LyndonZhang
交易清淡的DBV科技公司(纳斯达克股票代码:DBVT)因其自愿撤回其美国Viaskin Peanut营销申请用于治疗4-11岁儿童的花生过敏而在销售量下降62%。
该公司表示,该问题涉及制造程序和质量控制方面的数据不足。它计划尽快重新申请。
花生过敏竞争对手Aimmune Therapeutics(纳斯达克股票代码:AIMT)上市前上涨12%。
LyndonZhang
2018-12-20
LyndonZhang
仓位三分之一
LyndonZhang
2018-12-21
LyndonZhang
6.3几 离目标差一点
LyndonZhang
2018-12-20
LyndonZhang
长期持有 30亿美元市场
LyndonZhang
2018-12-20
LyndonZhang
看多到7+
什么也没有了~
APP内打开
发表看法
5
3
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":360451,"tweetId":"360451","gmtCreate":1545315250688,"gmtModify":1704784538747,"author":{"id":3468792081109004,"authorId":3468792081109004,"authorIdStr":"3468792081109004","name":"LyndonZhang","avatar":"https://static.tigerbbs.com/b32b514be3766ff3cd24f8a32801639c","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":9,"starInvestorFlag":false},"themes":[],"images":[{"img":"https://static.tigerbbs.com/58214cb5e58361bf490a7bde46680fac"}],"coverImages":[{"img":"https://static.tigerbbs.com/58214cb5e58361bf490a7bde46680fac"}],"extraTitle":"","html":"<html><head></head><body><p>$DBV Technologies S.A.(DBVT)$ 这就是大跌的原因</p> <img src=\"https://static.tigerbbs.com/58214cb5e58361bf490a7bde46680fac\"></body></html>","htmlText":"<html><head></head><body><p>$DBV Technologies S.A.(DBVT)$ 这就是大跌的原因</p> <img src=\"https://static.tigerbbs.com/58214cb5e58361bf490a7bde46680fac\"></body></html>","text":"$DBV Technologies S.A.(DBVT)$ 这就是大跌的原因","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":5,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/360451","repostId":0,"isVote":1,"tweetType":1,"viewCount":3102,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["DBVT"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":43,"xxTargetLangEnum":"ZH_CN"},"commentList":[{"id":1227325,"gmtCreate":1545315268770,"gmtModify":1545355308641,"authorId":3468792081109004,"author":{"id":3468792081109004,"authorId":3468792081109004,"name":"LyndonZhang","avatar":"https://static.tigerbbs.com/b32b514be3766ff3cd24f8a32801639c","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":360451,"type":1,"supId":0,"prevId":0,"content":"交易清淡的DBV科技公司(纳斯达克股票代码:DBVT)因其自愿撤回其美国Viaskin Peanut营销申请用于治疗4-11岁儿童的花生过敏而在销售量下降62%。\n<br>该公司表示,该问题涉及制造程序和质量控制方面的数据不足。它计划尽快重新申请。\n<br>花生过敏竞争对手Aimmune Therapeutics(纳斯达克股票代码:AIMT)上市前上涨12%。","text":"交易清淡的DBV科技公司(纳斯达克股票代码:DBVT)因其自愿撤回其美国Viaskin Peanut营销申请用于治疗4-11岁儿童的花生过敏而在销售量下降62%。\n<br>该公司表示,该问题涉及制造程序和质量控制方面的数据不足。它计划尽快重新申请。\n<br>花生过敏竞争对手Aimmune Therapeutics(纳斯达克股票代码:AIMT)上市前上涨12%。","html":"交易清淡的DBV科技公司(纳斯达克股票代码:DBVT)因其自愿撤回其美国Viaskin Peanut营销申请用于治疗4-11岁儿童的花生过敏而在销售量下降62%。\n<br>该公司表示,该问题涉及制造程序和质量控制方面的数据不足。它计划尽快重新申请。\n<br>花生过敏竞争对手Aimmune Therapeutics(纳斯达克股票代码:AIMT)上市前上涨12%。","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0},{"id":1227389,"gmtCreate":1545316335011,"gmtModify":1545316335011,"authorId":3468792081109004,"author":{"id":3468792081109004,"authorId":3468792081109004,"name":"LyndonZhang","avatar":"https://static.tigerbbs.com/b32b514be3766ff3cd24f8a32801639c","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":360451,"type":1,"supId":0,"prevId":0,"content":"仓位三分之一","text":"仓位三分之一","html":"仓位三分之一","likeSize":1,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0},{"id":1228309,"gmtCreate":1545341844158,"gmtModify":1545341844158,"authorId":3468792081109004,"author":{"id":3468792081109004,"authorId":3468792081109004,"name":"LyndonZhang","avatar":"https://static.tigerbbs.com/b32b514be3766ff3cd24f8a32801639c","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":360451,"type":1,"supId":0,"prevId":0,"content":"6.3几 离目标差一点","text":"6.3几 离目标差一点","html":"6.3几 离目标差一点","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0},{"id":1227438,"gmtCreate":1545316850201,"gmtModify":1545316850201,"authorId":3468792081109004,"author":{"id":3468792081109004,"authorId":3468792081109004,"name":"LyndonZhang","avatar":"https://static.tigerbbs.com/b32b514be3766ff3cd24f8a32801639c","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":360451,"type":1,"supId":0,"prevId":0,"content":"长期持有 30亿美元市场","text":"长期持有 30亿美元市场","html":"长期持有 30亿美元市场","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0},{"id":1227383,"gmtCreate":1545316293867,"gmtModify":1545316293867,"authorId":3468792081109004,"author":{"id":3468792081109004,"authorId":3468792081109004,"name":"LyndonZhang","avatar":"https://static.tigerbbs.com/b32b514be3766ff3cd24f8a32801639c","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":360451,"type":1,"supId":0,"prevId":0,"content":"看多到7+","text":"看多到7+","html":"看多到7+","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0}],"isCommentEnd":false,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/360451"}
精彩评论
该公司表示,该问题涉及制造程序和质量控制方面的数据不足。它计划尽快重新申请。
花生过敏竞争对手Aimmune Therapeutics(纳斯达克股票代码:AIMT)上市前上涨12%。